INIS
cancer
100%
receptors
100%
growth factors
75%
patients
50%
therapy
37%
radiations
25%
tumors
25%
diseases
25%
reviews
25%
management
25%
monoclonal antibodies
25%
surgery
12%
clinical trials
12%
detection
12%
populations
12%
applications
12%
usa
12%
kinases
12%
investigations
12%
antibodies
12%
metastases
12%
food and drug administration
12%
increasing
12%
side effects
12%
larynx
12%
oral cavity
12%
pharynx
12%
Medicine and Dentistry
Head and Neck Cancer
100%
Epidermal Growth Factor Receptor
75%
Cetuximab
50%
Patient
50%
Combination Therapy
37%
Development
25%
Receptor
25%
Monoclonal Antibody
25%
Therapeutic Procedure
25%
Radiation
25%
Diseases
12%
Surgery
12%
Neoplasm
12%
Side Effect
12%
Recurrent Disease
12%
Chemoradiotherapy
12%
Metastatic Carcinoma
12%
Antibody
12%
Larynx
12%
Phosphotransferase
12%
Multimodality Cancer Therapy
12%
Gefitinib
12%
Erlotinib
12%
Pharynx
12%
Introspection
12%
Radiosensitizer
12%
Mouth Tumor
12%
Targeted Therapy
12%
Mechanism of Action
12%
Hope
12%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Cancer
100%
Epidermal Growth Factor Receptor
75%
Cetuximab
50%
Receptor
25%
Monoclonal Antibody
25%
Clinical Trial
25%
Side Effect
12%
Diseases
12%
Neoplasm
12%
Recurrent Disease
12%
Antibody
12%
Phosphotransferase
12%
Metastasis
12%
Erlotinib
12%
Gefitinib
12%
Radiosensitizing Agent
12%
Mouth Tumor
12%